Đang chuẩn bị liên kết để tải về tài liệu:
Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

The oncogenic PI3K/Akt/mTOR pathway is frequently activated in HCC. Data on the mTOR inhibitor, temsirolimus, is limited in HCC patients with concomitant chronic liver disease. The objectives of this study were: (1) In phase I, to determine DLTs and MTD of temsirolimus in HCC patients with chronic liver disease; (2) In phase II, to assess activity of temsirolimus in HCC, and (3) to explore potential biomarkers for response. |

TÀI LIỆU LIÊN QUAN

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): Study protocol for a randomized phase III trial

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

Methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: A prospective randomized phase III study

Development, effectiveness and cost-effectiveness of a new out-patient Breathlessness Support Service: Study protocol of a phase III fast-track randomised controlled trial

Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): Study protocol for a randomised phase III trial

Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): Study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial

NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma

Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: A multicenter phase II study (TOSA trial) protocol

Enzalutamide versus abiraterone as a first-line endocrine therapy for castrationresistant prostate cancer (ENABLE study for PCa): A study protocol for a multicenter randomized phase III trial

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: Results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.